AI-Driven Biotech: Why These Three Stocks Matter for Investors

Artificial intelligence has become a game-changer for the biotechnology sector, fundamentally reshaping how companies discover and develop life-saving medicines. In the fast-evolving landscape of 2025 and into 2026, several biotech companies are leveraging cutting-edge AI capabilities to accelerate drug discovery timelines and unlock unprecedented growth potential. This convergence of artificial intelligence and biotechnology represents one of the most compelling investment themes for forward-thinking investors. Below are three standout stocks that exemplify how companies are harnessing AI to transform healthcare innovation.

AbbVie: Leading the Charge in AI-Powered Drug Discovery

AbbVie (NYSE: ABBV) stands as a heavyweight in the pharmaceutical industry, commanding a diverse portfolio across immunology, oncology, and neuroscience. The company’s recent financial performance has been robust, buoyed by exceptional sales of its flagship immunotherapy drugs Skyrizi and Rinvoq—positioned as next-generation alternatives to its legacy blockbuster Humira.

What truly sets AbbVie apart is its sophisticated approach to artificial intelligence integration. The company has developed the ARCH (AbbVie Research and Development Convergence Hub) platform, which harnesses the power of machine learning to mine vast datasets, streamline AI-driven drug discovery, and optimize molecular design. By embedding AI and machine learning into its R&D infrastructure, AbbVie aims to compress the traditional 10- to 15-year drug development cycle by half—a transformative capability in an industry where speed translates directly to competitive advantage and shareholder returns.

Management’s confidence is evident in their 2025 earnings guidance, projecting adjusted EPS growth of approximately 21% at the midpoint compared to the prior year. With a well-stocked pipeline of drug candidates and a management team committed to innovation, AbbVie appears positioned to deliver sustained value to long-term shareholders.

Gilead Sciences: The Steady Performer Embracing AI Collaboration

Gilead Sciences (NASDAQ: GILD) exemplifies the power of consistency in biotechnology investing. Over the past year, the stock has surged 26%, reaching levels not seen in nearly a decade—validating the company’s strategic direction and market strength.

Gilead has built its reputation on pioneering antiviral therapies, maintaining dominant market positions in HIV and hepatitis C treatments while successfully diversifying into oncology and other therapeutic areas. Recent quarterly results exceeded Wall Street expectations, with management raising full-year guidance amid robust demand across its product ecosystem, notably including Livdelzi for primary biliary cholangitis treatment.

The company is increasingly embracing artificial intelligence to strengthen its competitive moat. In early 2025, Gilead expanded its partnership with Cognizant to develop custom generative AI solutions aimed at enhancing operational efficiency. More significantly, the company established a collaboration with Terray Therapeutics, leveraging their proprietary tNova AI-powered drug discovery platform. This exclusive partnership grants Gilead the option to commercialize promising compounds developed through the AI-driven program. These strategic moves position Gilead to maintain its edge in an industry where technological innovation is paramount.

Moderna: A Turnaround Story with AI at Its Core

Moderna (NASDAQ: MRNA) presents a markedly different investment profile compared to AbbVie and Gilead. Once celebrated as the pioneer of mRNA vaccine technology, the company has faced headwinds from declining COVID-19 vaccine demand, resulting in a steep 64% stock decline over the past year—creating what many view as an opportune entry point for contrarian investors.

Yet Moderna is far from dormant. The company is aggressively pursuing next-generation vaccines, including formulations for norovirus and cytomegalovirus (CMV). A particularly significant development came in early 2025 when Moderna secured a $590 million government award to advance late-stage development of an H5N1 avian influenza vaccine—underscoring the strategic importance of its platform.

Central to Moderna’s renaissance strategy is the deployment of comprehensive artificial intelligence infrastructure. The company is constructing a cloud-native digital platform and integrating AI across its entire value chain through partnerships with technology leaders OpenAI and IBM. By weaving AI into every facet of mRNA development and manufacturing, Moderna has set an ambitious target: securing 10 new product approvals within a three-year timeframe. For investors who believe in the company’s ability to return to a growth trajectory, the current valuation may represent an attractive opportunity to accumulate shares before momentum accelerates.

The Convergence of AI and Biotech: A Long-Term Thesis

The intersection of artificial intelligence and biotechnology stocks continues to present compelling opportunities for investors seeking exposure to transformative healthcare innovation. Whether through AbbVie’s proprietary AI platforms, Gilead’s strategic AI partnerships, or Moderna’s comprehensive AI infrastructure rollout, these three companies are positioned at the forefront of AI-enabled drug development. As these artificial intelligence applications mature and deliver tangible clinical results, the long-term upside for AI biotech leaders could prove substantial for patient investors willing to hold through market cycles.